Zubsolv market share (rolling 4 weeks average) was more or less unchanged in May compared to the April numbers. In the last week of May (ending 26 of May) Zubsolv prescription recorded a market share of 5.28%, up by 0.03% from April. The market share, estimated as number of units, reached 5,43% at the end of May, up by 0.04% from April. The market for buprenorphine/naloxone products continues to show strong underlying growth, with a y/y growth rate of 11.3% (TRx) and 9.9% (units), on a monthly basis, at the end of May. We have raised our 2Q’17 earnings estimate, due to the milestone payment from Astrazeneca as OX-CLI advances into Phase I clinical trials. We now expect Orexo to show revenue of SEK 148.7 million in 2Q’17, compared to SEK 127.7 million previously. We also expect the payment will take Orexo to positive EBITDA as well as positive EBIT in 2Q’17.